

Supplemental Information

Discrimination of Enantiomers of Amides with Two Stereogenic Centers Enabled by Chiral Bisthiourea Derivatives as Chiral Solvating Agents Using ^1H NMR Spectroscopy

Hanchang Zhang,^a Hongmei Zhao,^b Jie Wen,^a Zhanbin Zhang,^a Pericles Stavropoulos,^c Yanlin Li,^a Lin Ai^{a*} and Jiaxin Zhang^{a*}

^aCollege of Chemistry, Beijing Normal University, Beijing 100875, People's Republic of China


^bState Key Laboratory of Information Photonics and Optical Communications, School of Science, Beijing University of Posts and Telecommunications, Beijing 100876, P. R. China

^cDepartment of Chemistry, Missouri University of Science and Technology, Rolla, Missouri 65409, USA

Contents

Synthesis of chiral bisthiourea derivatives 1–9 as CSAs.....	S2
Synthesis of enantiomers of amides with two stereogenic centers as guests.....	S4
NMR and HRMS spectra of chiral bisthiourea derivatives 1–9 as CSAs.....	S10
NMR and HRMS spectra of enantiomers of amides G16–27 as guests.....	S29
^1H NMR spectra of enantiomeric discrimination of (\pm)- G16–27 in the presence of CSAs 1–9	S78

Synthesis of chiral bithiourea derivatives 1–9 as CSAs.



General procedure of synthesis of chiral bithiourea derivatives 1–9: Chiral diamines **10** (R = Ph, Bn and *i*Pr) were prepared starting from (1*S*,2*S*)-(+)-1,2-diaminocyclohexane, *D*- α -amino acids (phenylglycine, phenylalanine and valine) according to reported procedures, respectively. Phenylthiocyanate or its respective derivatives **11** (4 mmol) in CH₂Cl₂ (5 mL) was added into a solution of the corresponding chiral diamines **10** (2 mmol) in CH₂Cl₂ (10 mL). And then, the mixture was stirred under a nitrogen atmosphere at room temperature and monitored by TLC. After the reaction was carried out, and the solvent was removed under reduced pressure. The residue was purified by column chromatography on silica gel to CSAs **1–9** in 55–67% yields.

(2*R*,2'*R*)-*N,N'*-((1*S*,2*S*)-cyclohexane-1,2-diyl)bis(2-phenyl-2-(3-phenylthioureido)acetamide) (CSA **1**): 58% yield; $R_f = 0.3$ (ethyl acetate / petroleum ether = 1/1); mp. 168–170 °C; $[\alpha]_D^{25} -8.9$ (*c* 2.5, THF); ¹H NMR (400 MHz, CDCl₃) δ : 1.06-1.11 (m, 2H), 1.15-1.20 (m, 2H), 1.61-1.66 (m, 2H), 1.82-1.85 (m, 2H), 3.63 (br, 2H), 5.95 (d, *J* = 6.96 Hz, 2H), 6.58 (d, *J* = 4.08 Hz, 2H), 7.23-7.42 (m, 20H), 7.48 (d, *J* = 6.92 Hz, 2H), 8.33 (s, 2H); ¹³C NMR (100 MHz, CDCl₃) δ : 24.3, 31.7, 54.4, 62.4, 124.9, 126.9, 127.5, 128.4, 129.0, 129.9, 136.6, 137.1, 171.1, 180.2; HRMS (ESI⁺-TOF) *m/z*: calcd for C₃₆H₃₉N₆O₂S₂ (M+H)⁺: 651.2570, found: 651.2571; IR (KBr): 3285, 2928, 2853, 1649, 1520, 1495, 756, 694 cm⁻¹.

(2*R*,2'*R*)-*N,N'*-((1*S*,2*S*)-cyclohexane-1,2-diyl)bis(3-phenyl-2-(3-phenylthioureido)propanamide) (CSA **2**): 63% yield; $R_f = 0.3$ (ethyl acetate / petroleum ether = 1/1); mp. 171–173 °C; $[\alpha]_D^{25} -37.8$ (*c* 2.5, THF); ¹H NMR (400 MHz, CDCl₃) δ : 0.89-0.97 (m, 2H), 1.14-1.19 (m, 2H), 1.61-1.64 (m, 2H), 1.75-1.78 (m, 2H), 2.99 (dd, *J* = 8.48 Hz, *J* = 13.68 Hz, 2H), 3.23 (dd, *J* = 6.32 Hz, *J* = 13.64 Hz, 2H), 3.41-3.45 (m, 2H), 5.03-5.09 (m, 2H), 6.19 (br, 2H), 6.92 (d, *J* = 7.52 Hz, 2H), 7.09-7.11 (m, 4H), 7.19-7.25 (m, 9H), 7.27-7.36 (m, 7H), 8.04 (br, 2H); ¹³C NMR (100 MHz, CDCl₃) δ : 24.1, 31.5, 38.0, 53.5, 59.4, 124.7, 126.6, 126.8, 128.4, 129.1, 129.6, 136.1, 136.2, 171.0, 179.6; HRMS (ESI⁺-TOF) *m/z*: calcd for C₃₈H₄₃N₆O₂S₂ (M+H)⁺: 679.2883, found: 679.2880; IR (KBr): 3310, 2926, 2855, 1655, 1524, 1499, 1354, 748, 698 cm⁻¹.

(2*R*,2'*R*)-*N,N'*-((1*S*,2*S*)-cyclohexane-1,2-diyl)bis(3-methyl-2-(3-phenylthioureido)butanamide) (CSA **3**): 55% yield; $R_f = 0.25$ (ethyl acetate / petroleum ether = 2/1); mp. 167–168 °C; $[\alpha]_D^{25} -11.9$ (*c* 2.5, THF); ¹H NMR (400 MHz, CDCl₃) δ : 0.96 (d, *J* = 6.56 Hz, 6H), 0.95-0.97 (m, 12H), 1.25-1.26 (m, 4H), 1.70 (br, 2H), 2.02-2.04 (m, 2H), 2.15-2.25 (m, 2H), 3.70 (br, 2H), 4.75-4.79 (m, 2H), 7.03-7.06 (m, 4H), 7.14-7.16 (m, 4H), 7.20-7.24 (m, 2H), 7.31-7.35 (m, 4H), 8.23 (br, 2H); ¹³C NMR (100 MHz, CDCl₃) δ : 18.7, 19.0, 24.4, 30.5, 32.0, 54.4, 63.6, 125.5, 126.9, 129.6, 136.9, 171.9, 180.9; HRMS (ESI⁺-TOF) *m/z*: calcd for C₃₀H₄₃N₆O₂S₂ (M+H)⁺: 583.2883, found: 583.2886; IR (KBr): 3287, 2930, 2857, 1643, 1603, 1528, 1350, 1319, 756, 698 cm⁻¹.

(2*R*,2'*R*)-*N,N'*-((1*S*,2*S*)-cyclohexane-1,2-diyl)bis(2-phenyl-2-(3-(2-(trifluoromethyl)phenyl)thioureido)acetamide) (CSA **4**): 62% yield; $R_f = 0.3$ (ethyl acetate / petroleum ether = 1/2); mp. 227–229 °C; $[\alpha]_D^{25} -32.7$ (*c*

2.5, THF); ^1H NMR (400 MHz, CDCl_3) δ : 1.03-1.05 (m, 4H), 1.55 (br, 2H), 1.78-1.80 (m, 2H), 3.59 (br, 2H), 5.95 (d, $J = 5.24$ Hz, 2H), 6.71 (br, 2H), 7.29-7.32 (m, 10H), 7.39-7.43 (m, 4H), 7.64-7.70 (m, 4H), 7.74-7.76 (m, 2H), 8.11 (br, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ : 24.0, 31.6, 54.3, 62.5, 123.2 (q, $J = 271.2$ Hz), 126.7 (q, $J = 29.3$ Hz), 127.0, 127.2, 127.7, 128.4, 129.0, 130.3, 133.1, 135.0, 137.0, 171.0, 181.6; ^{19}F NMR (376 MHz, CDCl_3) δ : -61.4; HRMS (ESI⁺-TOF) m/z : calcd for $\text{C}_{38}\text{H}_{37}\text{N}_6\text{O}_2\text{F}_6\text{S}_2$ (M+H)⁺: 787.2318, found: 787.2320; IR (KBr): 3283, 2936, 1647, 1543, 1321, 1173, 1126, 766, 701 cm^{-1} .

(2*R*,2'*R*)-*N,N'*-((1*S*,2*S*)-cyclohexane-1,2-diyl)bis(3-phenyl-2-(3-(2-(trifluoromethyl)phenyl)thioureido)propanamide) (CSA 5): 62% yield; $R_f = 0.3$ (ethyl acetate / petroleum ether = 1/1); mp. 129–130 °C; $[\alpha]_{\text{D}}^{25} -62.5$ (c 2.5, THF); ^1H NMR (400 MHz, CDCl_3) δ : 0.93-1.02 (m, 2H), 1.11-1.17 (m, 2H), 1.60-1.64 (m, 2H), 1.77-1.81 (m, 2H), 3.04 (dd, $J = 7.94$ Hz, $J = 13.70$ Hz, 2H), 3.18 (dd, $J = 6.02$ Hz, $J = 13.78$ Hz, 2H), 3.42-3.46 (m, 2H), 5.08-5.13 (m, 2H), 6.38 (d, $J = 5.08$ Hz, 2H), 6.83 (d, $J = 7.48$ Hz, 2H), 7.14-7.16 (m, 4H), 7.21-7.26 (m, 6H), 7.32 (d, $J = 7.88$ Hz, 2H), 7.38 (dd, $J = 7.56$ Hz, $J = 7.60$ Hz, 2H), 7.55 (dd, $J = 7.68$ Hz, $J = 7.56$ Hz, 2H), 7.66 (d, $J = 7.76$ Hz, 2H), 7.77 (br, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ : 24.2, 31.6, 38.1, 53.9, 59.6, 123.2 (q, $J = 271.8$ Hz), 126.5 (q, $J = 29.8$ Hz), 127.0, 127.3, 127.6, 128.6, 129.3, 130.0, 133.2, 134.5, 136.2, 171.2, 181.1; ^{19}F NMR (376 MHz, CDCl_3) δ : -61.5; HRMS (ESI⁺-TOF) m/z : calcd for $\text{C}_{40}\text{H}_{41}\text{N}_6\text{O}_2\text{F}_6\text{S}_2$ (M+H)⁺: 815.2631, found: 815.2633; IR (KBr): 3318, 2934, 2859, 1726, 1651, 1391, 1319, 1196, 1171, 1032, 766 cm^{-1} .

(2*R*,2'*R*)-*N,N'*-((1*S*,2*S*)-cyclohexane-1,2-diyl)bis(3-methyl-2-(3-(2-(trifluoromethyl)phenyl)thioureido)butanamide) (CSA 6): 61% yield; $R_f = 0.25$ (ethyl acetate / petroleum ether = 3/2); mp. 215–216 °C; $[\alpha]_{\text{D}}^{25} -5.0$ (c 2.5, THF); ^1H NMR (400 MHz, CDCl_3) δ : 0.90 (d, $J = 6.80$ Hz, 6H), 0.94 (d, $J = 6.72$ Hz, 6H), 1.27-1.29 (m, 4H), 1.73 (br, 2H), 2.03-2.05 (m, 2H), 2.15-2.25 (m, 2H), 3.71 (br, 2H), 4.80 (m, 2H), 7.06-7.08 (d, 2H), 7.11-7.12 (m, 2H), 7.38 (dd, $J = 7.16$ Hz, $J = 7.32$ Hz, 2H), 7.56 (dd, $J = 7.48$ Hz, $J = 7.32$ Hz, 2H), 7.66 (d, $J = 7.68$ Hz, 2H), 7.94 (br, 2H); ^{13}C NMR (100 MHz, $\text{DMSO}-d_6$) δ : 18.3, 19.2, 24.4, 32.2, 32.4, 51.5, 62.0, 122.7, 125.2 (q, $J = 28.7$ Hz), 125.4, 126.2 (q, $J = 4.78$ Hz), 126.8, 132.6, 132.7, 137.9, 170.6, 183.0; ^{19}F NMR (376 MHz, CDCl_3) δ : -61.5; HRMS (ESI⁺-TOF) m/z : calcd for $\text{C}_{32}\text{H}_{41}\text{N}_6\text{O}_2\text{F}_6\text{S}_2$ (M+H)⁺: 719.2631, found: 719.2629; IR (KBr): 3304, 2965, 2934, 1639, 1531, 1321, 1171, 1130, 1059, 764, 711 cm^{-1} .


(2*R*,2'*R*)-*N,N'*-((1*S*,2*S*)-cyclohexane-1,2-diyl)bis(2-(3-(3,5-bis(trifluoromethyl)phenyl)thioureido)-2-phenylacetamide) (CSA 7): 67% yield; $R_f = 0.3$ (ethyl acetate / petroleum ether = 2/3); mp. 153–155 °C; $[\alpha]_{\text{D}}^{25} -52.0$ (c 2.5, THF); ^1H NMR (400 MHz, CDCl_3) δ : 0.98-1.06 (m, 4H), 1.55-1.56 (m, 2H), 1.77-1.80 (m, 2H), 3.62 (br, 2H), 6.04 (br, 2H), 6.78 (br, 2H), 7.31-7.35 (m, 10H), 7.57 (s, 2H), 7.88 (s, 6H), 9.01 (br, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ : 24.0, 31.6, 54.4, 62.2, 118.6, 122.9 (q, $J = 271.2$ Hz), 123.3, 127.3, 128.9, 129.2, 132.0 (q, $J = 33.9$ Hz), 136.2, 139.8, 171.7, 180.6; ^{19}F NMR (376 MHz, CDCl_3) δ : -63.0; HRMS (ESI⁺-TOF) m/z : calcd for $\text{C}_{40}\text{H}_{35}\text{N}_6\text{O}_2\text{F}_{12}\text{S}_2$ (M+H)⁺: 923.2065, found: 923.2063; IR (KBr): 3428, 2934, 1653, 1516, 1383, 1279, 1180, 1134, 887, 700 cm^{-1} .

(2*R*,2'*R*)-*N,N'*-((1*S*,2*S*)-cyclohexane-1,2-diyl)bis(2-(3-(3,5-bis(trifluoromethyl)phenyl)thioureido)-3-phenylpropanamide) (CSA 8): 59% yield; $R_f = 0.3$ (ethyl acetate / petroleum ether = 1/1); mp. 199–200 °C; $[\alpha]_{\text{D}}^{25} -47.3$ (c 2.5, THF); ^1H NMR (400 MHz, CDCl_3) δ : 0.76 (br, 2H), 0.86-0.89 (m, 2H), 1.46 (br, 2H), 1.52-1.55 (m, 2H), 3.05-3.10 (m, 2H), 3.30-3.37 (m, 4H), 5.05 (br, 2H), 6.37 (br, 2H), 7.16-7.26 (m, 4H), 7.22 (br, 6H), 7.54-7.61 (m, 4H), 7.88 (s, 4H), 8.97 (br, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ : 23.8, 31.4, 38.9, 53.9, 60.1, 118.8, 122.9 (q, $J = 271.2$ Hz), 123.5, 127.4, 128.8, 129.2, 132.2 (q, $J = 33.8$ Hz), 135.7, 139.7, 171.6, 180.4; ^{19}F NMR (376 MHz, CDCl_3) δ : -63.0; HRMS (ESI⁺-TOF) m/z : calcd for $\text{C}_{42}\text{H}_{39}\text{N}_6\text{O}_2\text{F}_{12}\text{S}_2$ (M+H)⁺: 951.2378, found: 951.2381; IR (KBr): 3480, 3306, 3063, 1655, 1584, 1383, 1329, 1279, 1184, 1130, 849, 707 cm^{-1} .

(2*R*,2'*R*)-*N,N'*-((1*S*,2*S*)-cyclohexane-1,2-diyl)bis(2-(3-(3,5-bis(trifluoromethyl)phenyl)thioureido)-3-methylb

utanamide) (CSA **9**): 64% yield; $R_f = 0.25$ (ethyl acetate / petroleum ether = 2/1); mp. 214–216 °C; $[\alpha]_D^{25} -79.6$ (c 2.5, THF); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ : 1.00-1.02 (m, 12H), 1.16-1.22 (m, 4H), 1.67 (br, 2H), 2.01-2.03 (m, 2H), 2.23 (br, 2H), 3.65 (br, 2H), 4.79 (br, 2H), 6.94 (br, 2H), 7.36 (br, 2H), 7.60 (br, 2H), 7.83 (br, 4H), 8.84 (br, 2H); $^{13}\text{C NMR}$ (100 MHz, DMSO-d_6) δ : 22.4, 22.9, 28.2, 35.6, 35.7, 55.7, 65.4, 120.1, 125.4, 127.4 (q , $J = 273.4$ Hz), 134.3 (q , $J = 31.5$ Hz), 146.1, 173.9, 184.2; $^{19}\text{F NMR}$ (376 MHz, CDCl_3) δ : -63.1; HRMS (ESI⁺-TOF) m/z : calcd for $\text{C}_{34}\text{H}_{39}\text{N}_6\text{O}_2\text{F}_{12}\text{S}_2$ (M+H)⁺: 855.2378, found: 855.2381; IR (KBr): 3296, 2968, 2938, 2860, 1634, 1470, 1385, 1279, 1190, 1138, 1101, 885, 704 cm^{-1} .

Synthesis of enantiomers of amides with two stereogenic centers as guests.



General procedure of enantiomers of amides 16–27: *N*-Ts-*L*- and *D*- α -amino acids **12** and **14**, and chiral amines (*R*)- and (*S*)-**13** and **15** were derived from corresponding α -amino acids, respectively. *N*-Ts-*L*- or *D*- α -amino acids **12** or **14** (1.0 mmol) was added into a solution of the corresponding (*R*)- and (*S*)-**13** or **15** (1.0 mmol) in dried EtOAc (10 mL) at room temperature, respectively. DCC (1.05 mmol) dissolved in dried EtOAc (5 mL) was dropped into the stirred mixture at ice bath under nitrogen atmosphere. After the reaction was carried out, the reaction mixture was filtered. The filtrate was concentrated under reduced pressure, and the crude product was purified by column chromatography on silica gel to afford corresponding (*S,R*)-GX and (*R,S*)-GX (**X = 16–27**) in 50–68 % yields.

(*S,S*)-3-methyl-2-(4-methylphenylsulfonamido)-*N*-((*R*)-1-oxo-1-(phenylamino)propan-2-yl)butanamide ((*S,R*)-**G16**): 57% yield; $R_f = 0.3$ (ethyl acetate / petroleum ether = 1/1); mp. 221–223 °C; $[\alpha]_D^{25} +54.1$ (c 1.67, THF); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ : 0.80 (d, $J = 6.44$ Hz, 3H), 0.81 (d, $J = 6.56$ Hz, 3H), 1.39 (d, $J = 6.92$ Hz, 3H), 2.04-2.11 (m, 1H), 2.27 (s, 3H), 3.59 (dd, $J = 7.02$ Hz, $J = 6.04$ Hz, 2H), 4.57-4.64 (m, 1H), 6.09 (d, $J = 8.24$ Hz, 1H), 7.07-7.11 (m, 2H), 7.19 (d, $J = 8.00$ Hz, 2H), 7.27 (t, $J = 7.74$ Hz, 2H), 7.48 (d, $J = 7.88$ Hz, 2H), 7.74 (d, $J = 8.08$ Hz, 2H), 8.60 (s, 1H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ : 17.5, 17.6, 19.1, 21.4, 31.4, 49.7, 62.5, 120.1, 124.5, 127.2, 128.9, 129.7, 136.6, 137.7, 143.9, 170.1, 171.7; HRMS (ESI⁺-TOF) m/z : calcd for $\text{C}_{21}\text{H}_{28}\text{N}_3\text{O}_4\text{S}$ (M+H)⁺: 418.1795, found: 418.1792; IR (KBr): 3300, 3252, 2965, 1672, 1641, 1599, 1541, 1447, 1161, 1089, 754, 694 cm^{-1} .

(*R,S*)-3-methyl-2-(4-methylphenylsulfonamido)-*N*-((*S*)-1-oxo-1-(phenylamino)propan-2-yl)butanamide ((*R,S*)-**G16**): 62% yield; $R_f = 0.3$ (ethyl acetate / petroleum ether = 1/1); mp. 221–223 °C; $[\alpha]_D^{25} -53.8$ (c 1.67, THF); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ : 0.81 (d, $J = 8.00$ Hz, 6H), 1.38 (d, $J = 6.68$ Hz, 3H), 2.03-2.08 (m, 1H), 2.27 (s, 3H), 3.60 (dd, $J = 6.56$ Hz, $J = 6.24$ Hz, 1H), 4.59-4.62 (m, 1H), 6.08 (d, $J = 7.20$ Hz, 1H), 7.07-7.10 (m, 2H), 7.18 (d, $J = 7.64$ Hz, 2H), 7.24-7.28 (m, 2H), 7.48 (d, $J = 7.64$ Hz, 2H), 7.73 (d, $J = 7.76$ Hz, 2H), 8.58 (s, 1H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ : 17.5, 17.6, 19.1, 21.4, 31.4, 49.7, 62.5, 120.1, 124.5, 127.2, 128.9, 129.7, 136.7, 137.7, 143.9, 170.0, 171.7; HRMS (ESI⁺-TOF) m/z : calcd for $\text{C}_{21}\text{H}_{28}\text{N}_3\text{O}_4\text{S}$

(M+H)⁺: 418.1795, found: 418.1798; IR (KBr): 3300, 3254, 2965, 1667, 1641, 1541, 1447, 1329, 1159, 1088, 694 cm⁻¹.

(*S*)-*N*-((*R*)-1-((4-methoxyphenyl)amino)-1-oxopropan-2-yl)-3-methyl-2-(4-methylphenylsulfonamido)butanamide ((*S,R*)-**G17**): 55% yield; $R_f = 0.3$ (ethyl acetate / petroleum ether = 1/1); mp. 225–227 °C; $[\alpha]_D^{25} +177.8$ (*c* 1.67, DMSO); ¹H NMR (400 MHz, CDCl₃) δ : 0.81 (d, *J* = 4.72 Hz, 6H), 1.38 (d, *J* = 6.24 Hz, 3H), 2.06 (br, 1H), 2.30 (s, 3H), 3.54 (br, 1H), 3.77 (s, 3H), 4.54 (br, 1H), 5.85 (br, 1H), 6.81 (d, *J* = 8.16 Hz, 2H), 6.89 (d, *J* = 5.88 Hz, 1H), 7.20 (d, *J* = 7.12 Hz, 2H), 7.37 (d, *J* = 8.12 Hz, 2H), 7.73 (d, *J* = 7.40 Hz, 2H), 8.34 (s, 1H); ¹³C NMR (100 MHz, CDCl₃) δ : 17.5, 17.6, 19.1, 21.4, 31.4, 49.5, 55.5, 62.5, 114.1, 121.9, 127.2, 129.7, 130.7, 136.7, 143.8, 156.6, 169.8, 171.6; HRMS (ESI⁺-TOF) *m/z*: calcd for C₂₂H₃₀N₃O₅S (M+H)⁺: 448.1900, found: 448.1905; IR (KBr): 3294, 3258, 2963, 1641, 1541, 1514, 1447, 1242, 1159, 1088, 694 cm⁻¹.

(*R*)-*N*-((*S*)-1-((4-methoxyphenyl)amino)-1-oxopropan-2-yl)-3-methyl-2-(4-methylphenylsulfonamido)butanamide ((*R,S*)-**G17**): 61% yield; $R_f = 0.3$ (ethyl acetate / petroleum ether = 1/1); mp. 229–231 °C; $[\alpha]_D^{25} -177.6$ (*c* 1.67, DMSO); ¹H NMR (400 MHz, CDCl₃) δ : 0.81 (d, *J* = 6.72 Hz, 6H), 1.38 (d, *J* = 6.96 Hz, 3H), 2.02-2.08 (m, 1H), 2.30 (s, 3H), 3.56-3.59 (m, 1H), 3.76 (s, 3H), 4.54-4.61 (m, 1H), 6.03 (d, *J* = 8.44 Hz, 2H), 6.79 (d, *J* = 8.88 Hz, 2H), 7.00 (d, *J* = 7.68 Hz, 1H), 7.20 (d, *J* = 8.04 Hz, 2H), 7.36 (d, *J* = 8.88 Hz, 2H), 7.74 (d, *J* = 8.12 Hz, 2H), 8.41 (s, 1H); ¹³C NMR (100 MHz, CDCl₃) δ : 17.5, 19.1, 21.5, 29.7, 31.4, 49.6, 55.5, 62.5, 114.2, 121.8, 127.3, 129.8, 130.8, 130.8, 144.0, 156.7, 169.5, 171.4; HRMS (ESI⁺-TOF) *m/z*: calcd for C₂₂H₃₀N₃O₅NaS (M+Na)⁺: 470.1720, found: 470.1720; IR (KBr): 3296, 3267, 2965, 1643, 1541, 1514, 1449, 1244, 1159, 1090, 826, 694 cm⁻¹.

(*S*)-3-methyl-2-(4-methylphenylsulfonamido)-*N*-((*R*)-2-oxo-1-phenyl-2-(phenylamino)ethyl)butanamide ((*S,R*)-**G18**): 55% yield; $R_f = 0.25$ (ethyl acetate / petroleum ether = 3/2); mp. 256–258 °C; $[\alpha]_D^{25} -15.5$ (*c* 1.67, DMSO); ¹H NMR (400 MHz, CDCl₃) δ : 0.79 (2d, *J* = 7.56 Hz, *J* = 7.32 Hz, 6H), 1.97-2.04 (m, 1H), 2.29 (s, 3H), 3.54 (dd, *J* = 8.36 Hz, *J* = 6.28 Hz, 1H), 5.26 (d, *J* = 6.20 Hz, 2H), 7.01 (d, *J* = 6.64 Hz, 1H), 7.11-7.15 (m, 1H), 7.23 (d, *J* = 8.16 Hz, 2H), 7.30-7.34 (m, 8H), 7.45 (d, *J* = 7.68 Hz, 2H), 7.73 (d, *J* = 8.04 Hz, 2H); ¹³C NMR (100 MHz, DMSO-d₆) δ : 18.8, 19.3, 21.2, 31.5, 56.3, 61.8, 119.3, 124.1, 126.9, 127.3, 128.1, 128.8, 129.3, 129.4, 138.8, 138.9, 139.2, 142.5, 168.6, 170.1; HRMS (ESI⁺-TOF) *m/z*: calcd for C₂₆H₃₀N₃O₄S (M+H)⁺: 480.1951, found: 480.1950; IR (KBr): 3301, 3258, 2962, 1643, 1539, 1447, 1331, 1161, 1090, 752, 710 cm⁻¹.

(*R*)-3-methyl-2-(4-methylphenylsulfonamido)-*N*-((*S*)-2-oxo-1-phenyl-2-(phenylamino)ethyl)butanamide ((*R,S*)-**G18**): 61% yield; $R_f = 0.25$ (ethyl acetate / petroleum ether = 3/2); mp. 259–261 °C; $[\alpha]_D^{25} +15.1$ (*c* 1.67, DMSO); ¹H NMR (400 MHz, CDCl₃) δ : 0.79 (2d, *J* = 7.36 Hz, *J* = 7.36 Hz, 6H), 1.96-2.02 (m, 1H), 2.29 (s, 3H), 3.54 (dd, *J* = 7.48 Hz, *J* = 7.56 Hz, 1H), 5.26 (d, *J* = 6.28 Hz, 1H), 7.02-7.03 (m, 1H), 7.11-7.15 (m, 1H), 7.22 (d, *J* = 8.04 Hz, 1H), 7.30-7.34 (m, 9H), 7.45 (d, *J* = 8.00 Hz, 2H), 7.73 (d, *J* = 8.20 Hz, 2H); ¹³C NMR (100 MHz, DMSO-d₆) δ : 19.6, 20.2, 22.1, 32.4, 57.4, 62.8, 120.3, 125.0, 127.8, 128.3, 129.0, 129.7, 130.2, 130.4, 139.7, 140.1, 143.4, 169.5, 171.1; HRMS (ESI⁺-TOF) *m/z*: calcd for C₂₆H₃₀N₃O₄S (M+H)⁺: 480.1951, found: 480.1957; IR (KBr): 3306, 3253, 2965, 1643, 1539, 1447, 1329, 1161, 1090, 752, 712 cm⁻¹.

(*S*)-3-methyl-2-(4-methylphenylsulfonamido)-*N*-((*R*)-1-oxo-3-phenyl-1-(phenylamino)propan-2-yl)butanamide ((*S,R*)-**G19**): 66% yield; $R_f = 0.?$ (ethyl acetate / petroleum ether = 2/1); mp. 258–260 °C; $[\alpha]_D^{25} +11.7$ (*c* 1.67, DMSO); ¹H NMR (400 MHz, CDCl₃) δ : 0.69 (2d, *J* = 7.76 Hz, *J* = 7.52 Hz, 6H), 1.81-1.88 (m, 1H), 2.23 (s, 3H), 3.07 (dd, *J* = 13.68 Hz, *J* = 7.64 Hz, 1H), 3.15 (dd, *J* = 13.90 Hz, *J* = 7.26 Hz, 1H), 3.39 (dd, *J* = 7.14 Hz, *J* = 6.64 Hz, 1H), 4.63-4.69 (m, 1H), 5.42 (d, *J* = 8.16 Hz, 1H), 6.44 (d, *J* = 7.16 Hz, 1H), 7.09-7.12 (m, 1H), 7.16 (d, *J* = 7.88 Hz, 2H), 7.23 (d, *J* = 7.32 Hz, 2H), 7.29-7.31 (m, 5H), 7.39 (d, *J* = 7.96 Hz, 2H), 7.69 (d, *J* = 7.88 Hz, 2H), 7.77 (br, 1H); ¹³C NMR (100 MHz, DMSO-d₆) δ : 18.9, 20.3, 22.0, 32.1,

39.5, 55.7, 62.9, 120.6, 124.8, 127.6, 127.7, 129.3, 130.1, 130.4, 130.5, 138.7, 139.8, 140.2, 143.3, 171.1, 171.2; HRMS (ESI⁺-TOF) *m/z*: calcd for C₂₇H₃₂N₃O₄S (M+H)⁺: 494.2108, found: 494.2103; IR (KBr): 3298, 3255, 1674, 1645, 1537, 1323, 1155, 1090, 758, 696 cm⁻¹.

(*R*)-3-methyl-2-(4-methylphenylsulfonamido)-*N*-((*S*)-1-oxo-3-phenyl-1-(phenylamino)propan-2-yl)butanamide ((*R,S*)-**G19**): 58% yield; *R_f* = 0.3 (ethyl acetate / petroleum ether = 2/1); mp. 256–258 °C; [α]_D²⁵ -11.9 (*c* 1.67, DMSO); ¹H NMR (400 MHz, CDCl₃) δ : 0.69 (2d, *J* = 7.80 Hz, *J* = 7.20 Hz, 6H), 1.82-1.90 (m, 1H), 2.23 (s, 3H), 3.07 (dd, *J* = 14.0 Hz, *J* = 7.34 Hz, 1H), 3.15 (dd, *J* = 13.7 Hz, *J* = 7.14 Hz, 1H), 3.39 (dd, *J* = 7.00 Hz, *J* = 7.16 Hz, 1H), 4.63-4.69 (m, 1H), 5.40 (br, 1H), 6.42 (br, 1H), 7.11 (m, 1H), 7.16 (d, *J* = 7.88 Hz, 2H), 7.23 (d, *J* = 7.36 Hz, 2H), 7.29-7.31 (m, 5H), 7.39 (d, *J* = 7.64 Hz, 2H), 7.69 (d, *J* = 8.00 Hz, 2H), 7.76 (br, 1H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ : 18.9, 20.3, 22.0, 32.1, 39.5, 55.6, 62.9, 120.5, 124.8, 127.6, 127.7, 129.3, 130.1, 130.4, 130.5, 138.7, 139.8, 140.2, 143.3, 171.0, 171.2; HRMS (ESI⁺-TOF) *m/z*: calcd for C₂₇H₃₂N₃O₄S (M+H)⁺: 494.2108, found: 494.2103; IR (KBr): 3296, 3254, 2963, 1672, 1645, 1533, 1449, 1323, 1157, 1090, 756, 696 cm⁻¹.

(*S*)-2-(4-methylphenylsulfonamido)-*N*-((*R*)-2-oxo-1-phenyl-2-(phenylamino)ethyl)propanamide ((*S,R*)-**G20**): 50% yield; *R_f* = 0.3 (ethyl acetate / petroleum ether = 1/1); mp. 227–229 °C; [α]_D²⁵ -50.4 (*c* 1.67, THF); ¹H NMR (400 MHz, CDCl₃) δ : 1.24 (d, *J* = 7.52 Hz, 3H), 2.34 (s, 3H), 3.89-3.96 (m, 1H), 5.49 (d, *J* = 7.04 Hz, 1H), 5.70 (d, *J* = 7.96 Hz, 1H), 7.09-7.11 (m, 1H), 7.22-7.29 (m, 5H), 7.34-7.35 (m, 5H), 7.43 (d, *J* = 7.80 Hz, 2H), 7.51 (d, *J* = 6.88 Hz, 1H), 7.73 (d, *J* = 8.00 Hz, 2H), 7.82 (s, 2H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ : 20.4, 22.2, 52.9, 57.4, 120.5, 125.1, 127.9, 128.1, 129.1, 129.8, 130.2, 130.7, 139.5, 139.7, 140.0, 143.8, 169.6, 172.2; HRMS (ESI⁺-TOF) *m/z*: calcd for C₂₄H₂₆N₃O₄S (M+H)⁺: 452.1638, found: 452.1640; IR (KBr): 3302, 3262, 1645, 1539, 1341, 1163, 1091, 758, 696 cm⁻¹.

(*R*)-2-(4-methylphenylsulfonamido)-*N*-((*S*)-2-oxo-1-phenyl-2-(phenylamino)ethyl)propanamide ((*R,S*)-**G20**): 51% yield; *R_f* = 0.3 (ethyl acetate / petroleum ether = 1/1); mp. 226–228 °C; [α]_D²⁵ +50.9 (*c* 1.67, THF); ¹H NMR (400 MHz, CDCl₃) δ : 1.24 (d, *J* = 7.32 Hz, 3H), 2.33 (s, 3H), 3.90-3.97 (m, 1H), 5.51 (d, *J* = 7.00 Hz, 1H), 5.70 (d, *J* = 7.60 Hz, 1H), 7.07-7.11 (m, 1H), 7.22-7.28 (m, 5H), 7.33-7.34 (m, 5H), 7.43 (d, *J* = 7.92 Hz, 2H), 7.52 (d, *J* = 6.68 Hz, 1H), 7.73 (d, *J* = 8.00 Hz, 2H), 7.85 (s, 1H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ : 20.4, 22.2, 53.0, 57.5, 120.5, 125.1, 127.9, 128.1, 129.1, 129.8, 130.2, 130.7, 139.5, 139.7, 140.0, 143.8, 169.6, 172.2; HRMS (ESI⁺-TOF) *m/z*: calcd for C₂₄H₂₆N₃O₄S (M+H)⁺: 452.1638, found: 452.1645; IR (KBr): 3310, 3254, 1647, 1541, 1443, 1337, 1163, 1092, 754, 696 cm⁻¹.

(*S*)-*N*-((*R*)-2-((4-methoxyphenyl)amino)-2-oxo-1-phenylethyl)-2-(4-methylphenylsulfonamido)propanamide ((*S,R*)-**G21**): 59% yield; *R_f* = 0.3 (ethyl acetate / petroleum ether = 1/1); mp. 213–215 °C; [α]_D²⁵ -8.5 (*c* 1.67, DMSO); ¹H NMR (400 MHz, CDCl₃) δ : 1.24 (d, *J* = 7.00 Hz, 3H), 2.34 (s, 3H), 3.76 (s, 3H), 3.91-3.94 (m, 1H), 5.49 (d, *J* = 6.48 Hz, 1H), 5.72-5.73 (m, 1H), 6.79 (d, *J* = 8.48 Hz, 2H), 7.22-7.24 (m, 3H), 7.33 (br, 6H), 7.53-7.54 (m, 1H), 7.71-7.77 (m, 3H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ : 20.3, 22.2, 52.9, 56.6, 57.4, 115.4, 121.9, 127.9, 128.0, 129.0, 129.8, 130.7, 133.2, 139.5, 139.9, 143.8, 156.9, 169.0, 172.1; HRMS (ESI⁺-TOF) *m/z*: calcd for C₂₅H₂₈N₃O₅S (M+H)⁺: 482.1744, found: 482.1748; IR (KBr): 3423, 3271, 1645, 1543, 1516, 1248, 1163, 1092, 700 cm⁻¹.

(*R*)-*N*-((*S*)-2-((4-methoxyphenyl)amino)-2-oxo-1-phenylethyl)-2-(4-methylphenylsulfonamido)propanamide ((*R,S*)-**G21**): 62% yield; *R_f* = 0.3 (ethyl acetate / petroleum ether = 1/1); mp. 203–205 °C; [α]_D²⁵ +8.4 (*c* 1.67, DMSO); ¹H NMR (400 MHz, CDCl₃) δ : 1.24 (d, *J* = 7.00 Hz, 3H), 2.34 (s, 3H), 3.76 (s, 3H), 3.90-3.94 (m, 1H), 5.48 (d, *J* = 6.96 Hz, 1H), 5.67 (d, *J* = 7.40 Hz, 1H), 6.80 (d, *J* = 8.80 Hz, 2H), 7.22-7.33 (m, 10H), 7.50 (d, *J* = 6.72 Hz, 1H), 7.70-7.74 (m, 3H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ : 20.4, 22.2, 53.0, 57.5, 120.5, 125.1, 127.9, 128.1, 129.1, 129.8, 130.2, 130.7, 139.5, 139.7, 140.0, 143.8, 169.6, 172.2; HRMS (ESI⁺-TOF) *m/z*: calcd for C₂₅H₂₈N₃O₅S (M+H)⁺: 482.1744, found: 482.1747; IR (KBr): 3298, 3269, 1645,

1601, 1543, 1337, 1242, 1163, 833, 700 cm⁻¹.

(*R*)-2-((*S*)-2-(4-methylphenylsulfonamido)propanamido)-*N*,3-diphenylpropanamide ((*S,R*)-**G22**): 55% yield; $R_f = 0.25$ (ethyl acetate / petroleum ether = 1/1); mp. 199–201 °C; $[\alpha]_D^{25} -5.0$ (*c* 1.67, THF); ¹H NMR (400 MHz, CDCl₃) δ : 1.10 (d, *J* = 6.88 Hz, 3H), 2.30 (s, 3H), 3.05 (dd, *J* = 13.70 Hz, *J* = 7.38 Hz, 1H), 3.14 (dd, *J* = 13.33 Hz, *J* = 7.22 Hz, 1H), 3.80–3.83 (m, 1H), 4.66–4.71 (m, 1H), 5.85 (d, *J* = 7.56 Hz, 1H), 7.04–7.10 (m, 2H), 7.20–7.25 (m, 9H), 7.37 (d, *J* = 7.84 Hz, 2H), 7.71 (d, *J* = 7.72 Hz, 2H), 7.98 (s, 1H); ¹³C NMR (100 MHz, CDCl₃) δ : 19.0, 21.4, 38.1, 52.7, 55.5, 120.2, 124.6, 127.1, 128.7, 128.9, 129.3, 129.8, 136.4, 136.8, 137.3, 143.9, 169.0, 172.2; HRMS (ESI⁺-TOF) *m/z*: calcd for C₂₅H₂₈N₃O₄S (M+H)⁺: 466.1795, found: 466.1794; IR (KBr): 3310, 3242, 1651, 1537, 1443, 1333, 1163, 1090, 752, 700 cm⁻¹.

(*S*)-2-((*R*)-2-(4-methylphenylsulfonamido)propanamido)-*N*,3-diphenylpropanamide ((*R,S*)-**G22**): 60% yield; $R_f = 0.25$ (ethyl acetate / petroleum ether = 1/1); mp. 198–200 °C; $[\alpha]_D^{25} +5.9$ (*c* 1.67, THF); ¹H NMR (400 MHz, CDCl₃) δ : 1.07 (d, *J* = 6.92 Hz, 3H), 2.27 (s, 3H), 3.01 (dd, *J* = 13.58 Hz, *J* = 7.62 Hz, 1H), 3.15 (dd, *J* = 13.62 Hz, *J* = 7.02 Hz, 1H), 3.84–3.88 (m, 1H), 4.70–4.76 (m, 1H), 6.20 (d, *J* = 7.92 Hz, 1H), 7.05–7.09 (m, 1H), 7.17–7.28 (m, 10H), 7.37 (d, *J* = 7.84 Hz, 2H), 7.70 (d, *J* = 7.96 Hz, 2H), 8.21 (s, 1H); ¹³C NMR (100 MHz, CDCl₃) δ : 19.0, 21.4, 38.1, 52.7, 55.5, 120.2, 124.6, 127.1, 128.7, 128.9, 129.3, 129.8, 136.4, 136.8, 137.3, 143.9, 169.0, 172.3; HRMS (ESI⁺-TOF) *m/z*: calcd for C₂₅H₂₈N₃O₄S (M+H)⁺: 466.1795, found: 466.1804; IR (KBr): 3300, 3273, 1649, 1543, 1441, 1319, 1159, 1084, 748, 698 cm⁻¹.

(*R*)-*N*-(4-methoxyphenyl)-2-((*S*)-2-(4-methylphenylsulfonamido)propanamido)-3-phenylpropanamide ((*S,R*)-**G23**): 57% yield; $R_f = 0.25$ (ethyl acetate / petroleum ether = 1/1); mp. 217–219 °C; $[\alpha]_D^{25} -14.3$ (*c* 1.67, DMSO); ¹H NMR (400 MHz, CDCl₃) δ : 1.15 (d, *J* = 7.04 Hz, 3H), 2.33 (s, 3H), 3.10 (d, *J* = 7.24 Hz, 2H), 3.77 (s, 3H), 4.58–4.63 (m, 1H), 5.37 (d, *J* = 7.40 Hz, 1H), 6.78–6.82 (m, 3H), 7.21–7.25 (m, 5H), 7.27–7.32 (m, 4H), 7.55 (s, 1H), 7.72 (d, *J* = 8.12 Hz, 2H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ : 20.8, 22.7, 40.2, 53.5, 55.8, 57.1, 115.8, 122.6, 128.2, 128.3, 129.8, 131.1, 133.8, 139.2, 140.2, 144.2, 157.3, 171.0, 172.7; HRMS (ESI⁺-TOF) *m/z*: calcd for C₂₆H₃₀N₃O₅S (M+H)⁺: 496.1900, found: 496.1898; IR (KBr): 3453, 3269, 1649, 1599, 1514, 1236, 1161, 1094, 976, 818, 702 cm⁻¹.

(*S*)-*N*-(4-methoxyphenyl)-2-((*R*)-2-(4-methylphenylsulfonamide)propanamido)-3-phenylpropanamide ((*R,S*)-**G23**): 60% yield; $R_f = 0.25$ (ethyl acetate / petroleum ether = 1/1); mp. 215–217 °C; $[\alpha]_D^{25} +14.1$ (*c* 1.67, DMSO); ¹H NMR (400 MHz, CDCl₃) δ : 1.14 (d, *J* = 7.00 Hz, 3H), 2.33 (s, 3H), 3.05–3.14 (m, 2H), 3.77 (s, 3H), 4.60–4.65 (m, 1H), 5.51 (d, *J* = 7.32 Hz, 1H), 6.80 (d, *J* = 8.92 Hz, 2H), 6.86 (d, *J* = 8.00 Hz, 1H), 7.21–7.25 (m, 5H), 7.27–7.30 (m, 4H), 7.63 (s, 1H), 7.71 (d, *J* = 8.12 Hz, 2H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ : 20.3, 22.1, 39.6, 53.0, 55.3, 56.5, 115.3, 122.1, 127.7, 127.8, 129.3, 130.6, 133.3, 138.7, 139.7, 143.6, 156.7, 170.5, 172.1; HRMS (ESI⁺-TOF) *m/z*: calcd for C₂₆H₃₀N₃O₅S (M+H)⁺: 496.1900, found: 496.1897; IR (KBr): 3258, 2924, 1649, 1537, 1516, 1333, 1240, 1163, 1092, 822, 702 cm⁻¹.

(*S*)-2-(4-methylphenylsulfonamido)-*N*-((*R*)-2-oxo-1-phenyl-2-(phenylamino)ethyl)-3-phenylpropanamide ((*S,R*)-**G24**): 61% yield; $R_f = 0.25$ (ethyl acetate / petroleum ether = 2/1); mp. 241–243 °C; $[\alpha]_D^{25} -11.4$ (*c* 1.67, THF); ¹H NMR (400 MHz, CDCl₃) δ : 2.31 (s, 3H), 2.91–3.00 (m, 2H), 3.97–4.02 (m, 1H), 5.44 (d, *J* = 7.08 Hz, 1H), 5.46 (d, *J* = 8.16 Hz, 1H), 6.88 (d, *J* = 7.32 Hz, 2H), 7.05–7.10 (m, 2H), 7.12–7.15 (m, 3H), 7.24–7.28 (m, 6H), 7.30–7.33 (m, 3H), 7.44 (d, *J* = 8.04 Hz, 2H), 7.56 (d, *J* = 8.12 Hz, 2H), 7.70 (s, 1H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ : 22.1, 39.9, 57.4, 58.5, 120.4, 125.0, 127.6, 127.7, 128.0, 128.9, 129.2, 129.8, 130.3, 130.4, 130.7, 138.3, 139.6, 140.1, 143.4, 169.6, 171.3; HRMS (ESI⁺-TOF) *m/z*: calcd for C₃₀H₃₀N₃O₄S (M+H)⁺: 528.1951, found: 528.1950; IR (KBr): 3314, 3250, 1672, 1641, 1539, 1447, 1333, 1161, 1089, 746, 696 cm⁻¹.

(*R*)-2-(4-methylphenylsulfonamido)-*N*-((*S*)-2-oxo-1-phenyl-2-(phenylamino)ethyl)-3-phenylpropanamide ((*R,S*)-**G24**): 58% yield; $R_f = 0.25$ (ethyl acetate / petroleum ether = 2/1); mp. 241–243 °C; $[\alpha]_D^{25} +11.3$ (*c*

1.67, THF); ^1H NMR (400 MHz, CDCl_3) δ : 2.30 (s, 3H), 2.95 (d, $J = 6.92$ Hz, 2H), 3.98-4.03 (m, 1H), 5.45 (d, $J = 7.00$ Hz, 1H), 5.50 (d, $J = 7.52$ Hz, 1H), 6.88 (d, $J = 7.24$ Hz, 2H), 7.07-7.15 (m, 6H), 7.23-7.26 (m, 3H), 7.27-7.32 (m, 5H), 7.44 (d, $J = 7.88$ Hz, 2H), 7.56 (d, $J = 8.20$ Hz, 2H), 7.73 (s, 1H); ^{13}C NMR (100 MHz, DMSO-d_6) δ : 22.1, 39.9, 57.4, 58.5, 120.4, 125.0, 127.6, 127.7, 128.0, 128.9, 129.2, 129.8, 130.2, 130.4, 130.7, 138.3, 139.6, 140.1, 143.4, 169.6, 171.3; HRMS (ESI⁺-TOF) m/z : calcd for $\text{C}_{30}\text{H}_{30}\text{N}_3\text{O}_4\text{S}$ (M+H)⁺: 528.1951, found: 528.1957; IR (KBr): 3306, 3252, 3032, 1670, 1643, 1537, 1447, 1333, 1161, 1088, 696 cm^{-1} .

(*S*)-*N*-((*R*)-2-oxo-1-phenyl-2-(phenylamino)ethyl)-1-tosylpyrrolidine-2-carboxamide ((*S,R*)-G25): 68% yield; $R_f = 0.25$ (ethyl acetate / petroleum ether = 1/2); mp. 216–218 °C; $[\alpha]_{\text{D}}^{25} -142.4$ (c 1.67, THF); ^1H NMR (400 MHz, CDCl_3) δ : 1.66-1.73 (m, 2H), 1.88 (br, 1H), 2.14 (br, 1H), 2.43 (s, 3H), 3.23-3.25 (m, 1H), 3.61 (br, 1H), 4.18 (d, $J = 6.76$ Hz, 1H), 5.76 (d, $J = 6.96$ Hz, 1H), 7.06-7.08 (m, 1H), 7.25-7.26 (m, 2H), 7.30-7.37 (m, 5H), 7.49 (br, 4H), 7.73 (d, $J = 7.40$ Hz, 2H), 7.96 (d, $J = 6.44$ Hz, 1H), 8.38 (s, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ : 21.6, 24.6, 30.4, 49.8, 58.1, 62.4, 119.9, 124.5, 127.4, 127.9, 128.6, 128.9, 129.2, 130.0, 133.1, 136.5, 137.6, 144.4, 167.9, 171.3; HRMS (ESI⁺-TOF) m/z : calcd for $\text{C}_{26}\text{H}_{28}\text{N}_3\text{O}_4\text{S}$ (M+H)⁺: 478.1795, found: 478.1793; IR (KBr): 3300, 3273, 1694, 1657, 1601, 1530, 1356, 1161, 1098, 758, 696 cm^{-1} .

(*R*)-*N*-((*S*)-2-oxo-1-phenyl-2-(phenylamino)ethyl)-1-tosylpyrrolidine-2-carboxamide ((*R,S*)-G25): 59% yield; $R_f = 0.25$ (ethyl acetate / petroleum ether = 1/2); mp. 215–217 °C; $[\alpha]_{\text{D}}^{25} +142.7$ (c 1.67, THF); ^1H NMR (400 MHz, CDCl_3) δ : 1.66-1.70 (m, 2H), 1.86-1.90 (m, 1H), 2.14-2.17 (m, 1H), 2.43 (s, 3H), 3.23-3.27 (m, 1H), 3.60-3.62 (m, 1H), 4.18 (d, $J = 6.32$ Hz, 1H), 5.76 (d, $J = 7.12$ Hz, 1H), 7.04-7.08 (m, 1H), 7.23-7.26 (m, 2H), 7.30-7.37 (m, 5H), 7.50 (br, 4H), 7.73 (d, $J = 7.52$ Hz, 2H), 7.97 (d, $J = 6.68$ Hz, 1H), 8.40 (s, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ : 21.6, 24.6, 30.4, 49.8, 58.1, 62.4, 119.9, 124.4, 127.4, 127.9, 128.6, 128.9, 129.2, 130.0, 133.1, 136.6, 137.6, 144.4, 167.9, 171.3; HRMS (ESI⁺-TOF) m/z : calcd for $\text{C}_{26}\text{H}_{28}\text{N}_3\text{O}_4\text{S}$ (M+H)⁺: 478.1795, found: 478.1798; IR (KBr): 3300, 1692, 1655, 1601, 1530, 1445, 1356, 1161, 1099, 758, 692 cm^{-1} .

(*S*)-*N*-((*R*)-2-((4-methoxyphenyl)amino)-2-oxo-1-phenylethyl)-1-tosylpyrrolidine-2-carboxamide ((*S,R*)-G26): 63% yield; $R_f = 0.25$ (ethyl acetate / petroleum ether = 2/1); mp. 171–173 °C; $[\alpha]_{\text{D}}^{25} -122.1$ (c 1.67, THF); ^1H NMR (400 MHz, CDCl_3) δ : 1.61-1.71 (m, 2H), 1.82-1.94 (m, 1H), 2.12-2.16 (m, 1H), 2.42 (s, 3H), 3.20-3.28 (m, 1H), 3.58-3.63 (m, 1H), 3.75 (s, 3H), 4.15-4.18 (m, 1H), 5.72 (d, $J = 7.52$ Hz, 1H), 6.78 (d, $J = 8.96$ Hz, 2H), 7.29-7.39 (m, 7H), 7.49 (d, $J = 6.92$ Hz, 2H), 7.73 (d, $J = 8.16$ Hz, 2H), 7.95 (d, $J = 7.52$ Hz, 1H), 8.27 (s, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ : 21.6, 24.6, 30.4, 49.8, 55.4, 58.0, 62.4, 114.0, 121.7, 127.4, 127.9, 128.6, 129.2, 129.4, 130.7, 133.2, 136.8, 144.3, 156.5, 167.7, 171.3; HRMS (ESI⁺-TOF) m/z : calcd for $\text{C}_{27}\text{H}_{30}\text{N}_3\text{O}_5\text{S}$ (M+H)⁺: 508.1900, found: 508.1904; IR (KBr): 3310, 1653, 1609, 1514, 1338, 1159, 1028, 839, 694 cm^{-1} .

(*R*)-*N*-((*S*)-2-((4-methoxyphenyl)amino)-2-oxo-1-phenylethyl)-1-tosylpyrrolidine-2-carboxamide ((*R,S*)-G26): 65% yield; $R_f = 0.25$ (ethyl acetate / petroleum ether = 2/1); mp. 171–173 °C; $[\alpha]_{\text{D}}^{25} +121.8$ (c 1.67, THF); ^1H NMR (400 MHz, CDCl_3) δ : 1.62-1.71 (m, 2H), 1.83-1.89 (m, 1H), 2.12-2.16 (m, 1H), 2.43 (s, 3H), 3.20-3.26 (m, 1H), 3.58-3.63 (m, 1H), 3.75 (s, 3H), 4.16 (d, $J = 6.00$ Hz, 1H), 5.71 (d, $J = 7.44$ Hz, 1H), 6.78 (d, $J = 8.88$ Hz, 2H), 7.29-7.39 (m, 7H), 7.49 (d, $J = 7.00$ Hz, 2H), 7.72 (d, $J = 8.04$ Hz, 1H), 8.21 (s, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ : 21.6, 24.6, 30.4, 49.8, 55.4, 58.0, 62.4, 114.0, 121.7, 127.4, 127.9, 128.6, 129.2, 130.0, 130.7, 133.2, 136.7, 144.3, 156.5, 167.7, 171.3; HRMS (ESI⁺-TOF) m/z : calcd for $\text{C}_{27}\text{H}_{30}\text{N}_3\text{O}_5\text{S}$ (M+H)⁺: 508.1900, found: 508.1898; IR (KBr): 3308, 1686, 1653, 1609, 1514, 1339, 1250, 1159, 1028, 823, 698 cm^{-1} .

(*S*)-*N*-((*R*)-1-oxo-3-phenyl-1-(phenylamino)propan-2-yl)-1-tosylpyrrolidine-2-carboxamide ((*S,R*)-G27): 65%

yield; $R_f = 0.3$ (ethyl acetate / petroleum ether = 1/2); mp. 181–183 °C; $[\alpha]_D^{25} -59.4$ (c 1.67, THF); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ : 1.54-1.58 (m, 1H), 1.62-1.69 (m, 2H), 2.02-2.04 (m, 1H), 2.44 (s, 3H), 3.10-3.16 (m, 1H), 3.31 (d, $J = 7.24$ Hz, 2H), 3.46-3.51 (m, 1H), 4.02-4.04 (m, 1H), 4.62-4.67 (m, 1H), 7.05-7.09 (m, 1H), 7.25-7.29 (m, 3H), 7.30-7.35 (m, 7H), 7.44 (d, $J = 7.64$ Hz, 2H), 7.72 (d, $J = 8.24$ Hz, 2H), 7.99 (s, 1H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ : 21.6, 24.4, 30.4, 37.0, 49.7, 56.1, 62.4, 120.0, 124.3, 127.0, 127.9, 128.8, 128.9, 129.5, 130.0, 132.7, 136.9, 137.6, 144.6, 168.6, 171.2; HRMS (ESI⁺-TOF) m/z : calcd for $\text{C}_{27}\text{H}_{30}\text{N}_3\text{O}_4\text{S}$ ($\text{M}+\text{H}$)⁺: 492.1951, found: 492.1950; IR (KBr): 3345, 3310, 2924, 2864, 1695, 1653, 1524, 1335, 1155, 1095, 698, 662 cm^{-1} .

(*R*)-*N*-((*S*)-1-oxo-3-phenyl-1-(phenylamino)propan-2-yl)-1-tosylpyrrolidine-2-carboxamide ((*R,S*)-**G27**): 57% yield; $R_f = 0.3$ (ethyl acetate / petroleum ether = 1/2); mp. 180–182 °C; $[\alpha]_D^{25} +59.2$ (c 1.67, THF); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ : 1.54-1.58 (m, 1H), 1.61-1.69 (m, 2H), 1.98-2.04 (m, 1H), 2.43 (s, 3H), 3.09-3.15 (m, 1H), 3.30 (d, $J = 7.20$ Hz, 2H), 3.47-3.52 (m, 1H), 4.02-4.05 (m, 1H), 4.65-4.71 (m, 1H), 7.04-7.08 (m, 1H), 7.24-7.28 (m, 3H), 7.30-7.36 (m, 7H), 7.44 (d, $J = 7.68$ Hz, 2H), 7.72 (d, $J = 8.24$ Hz, 2H), 8.18 (s, 1H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ : 21.6, 24.4, 30.4, 37.1, 49.7, 56.0, 62.4, 120.0, 124.3, 127.0, 127.9, 128.8, 128.8, 129.5, 130.0, 132.7, 136.9, 137.7, 144.6, 168.6, 171.8; HRMS (ESI⁺-TOF) m/z : calcd for $\text{C}_{27}\text{H}_{30}\text{N}_3\text{O}_4\text{S}$ ($\text{M}+\text{H}$)⁺: 492.1951, found: 492.1960; IR (KBr): 3343, 3310, 2924, 2864, 1695, 1653, 1518, 1447, 1335, 1155, 1098, 748, 698, 662 cm^{-1} .

NMR and HRMS spectra of chiral bithiourea derivatives 1–9 as CSAs.




Figure S1. ¹H NMR Spectrum of CSA 1 in CDCl₃ (400 MHz).




Figure S2. ¹H NMR spectrum of CSA 1 in CDCl₃ (5% D₂O) (400 MHz).




Figure S3. ¹³C NMR spectrum of CSA 1 in CDCl₃ (100 MHz).




Figure S4. HRMS spectrum of CSA 1.




Figure S5. ¹H NMR spectrum of CSA 2 in CDCl₃ (400 MHz).




Figure S6. ¹H NMR spectrum of CSA 2 in CDCl₃ (5% D₂O) (400 MHz).




Figure S7. ^{13}C NMR spectrum of CSA 2 in CDCl_3 (100 MHz).




Figure S8. HRMS spectrum of CSA 2.




Figure S9. ^1H NMR spectrum of CSA 3 in CDCl_3 (400 MHz).




Figure S10. ^{13}C NMR spectrum of CSA 3 in CDCl_3 (100 MHz).




Figure S11. HRMS spectrum of CSA 3.




Figure S12. ¹H NMR spectrum of CSA 4 in CDCl₃ (400 MHz).




Figure S13. ¹³C NMR spectrum of CSA 4 in CDCl₃ (100 MHz).




Figure S14. ¹⁹F NMR spectrum of CSA 4 in CDCl₃ (376 MHz).




Figure S15. HRMS spectrum of CSA 4.




Figure S16. ¹H NMR spectrum of CSA 5 in CDCl₃ (400 MHz).




Figure S17. ^1H NMR spectrum of CSA **5** in CDCl_3 (5% D_2O) (400 MHz).




Figure S18. ^{13}C NMR spectrum of CSA **5** in CDCl_3 (100 MHz).




Figure S19. ^{19}F NMR spectrum of CSA 5 in CDCl_3 (376 MHz).




Figure S20. HRMS spectrum of CSA 5.




Figure S21. ¹H NMR spectrum of CSA 6 in CDCl₃ (400 MHz).




Figure S22. ¹H NMR spectrum of CSA 6 in CDCl₃ (5% D₂O) (400 MHz).




Figure S25. HRMS spectrum of CSA 6.




Figure S26. ^1H NMR spectrum of CSA 7 in CDCl_3 (400 MHz).




Figure S27. ^{13}C NMR spectrum of CSA 7 in CDCl_3 (100 MHz).




Figure S28. ^{19}F NMR spectrum of CSA 7 in CDCl_3 (376 MHz).




Figure S29. HRMS spectrum of CSA 7.




Figure S30. ¹H NMR spectrum of CSA 8 in CDCl₃ (400 MHz).




Figure S31. ¹³C NMR spectrum of CSA 8 in CDCl₃ (100 MHz).




Figure S32. ¹⁹F NMR spectrum of CSA 8 in CDCl₃ (376 MHz).




Figure S33. HRMS spectrum of CSA 8.




Figure S34. ¹H NMR spectrum of CSA 9 in CDCl₃ (400 MHz).




Figure S35. ¹H NMR spectrum of CSA 9 in CDCl₃ (5% D₂O) (400 MHz).




Figure S36. ¹³C NMR spectrum of CSA 9 in DMSO-*d*₆ (100 MHz).




Figure S37. ^{19}F NMR spectrum of CSA **9** in CDCl_3 (376 MHz).




Figure S38. HRMS spectrum of CSA **9**.

NMR and HRMS spectra of enantiomers of amides G16–27 as guests.




Figure S39. ¹H NMR spectrum of (S,R)-G16 in CDCl₃ (400 MHz).




Figure S40. ¹³C NMR spectrum of (S,R)-G16 in CDCl₃ (100 MHz).




Figure S41. HRMS spectrum of (*S,R*)-G16.




Figure S42. ¹H NMR spectrum of (*R,S*)-G16 in CDCl₃ (400 MHz).




Figure S43. ^{13}C NMR spectrum of (*R,S*)-G16 in CDCl_3 (100 MHz).




Figure S44. ^1H - ^1H COSY spectrum of (*R,S*)-G16 in CDCl_3 (400 MHz).




Figure S45. HSQC spectrum of (R,S)-G16 in CDCl₃.




Figure S46. HRMS spectrum of (R,S)-G16.




Figure S47. ¹H NMR spectrum of (*S,R*)-G17 in CDCl₃ (400 MHz).




Figure S48. ¹H-¹H COSY spectrum of (*S,R*)-G17 in CDCl₃ (400 MHz).




Figure S49. ¹³C NMR spectrum of (S,R)-G17 in CDCl₃ (100 MHz).




Figure S50. HRMS spectrum of (S,R)-G17.




Figure S51. ¹H NMR spectrum of (*R,S*)-G17 in CDCl₃ (400 MHz).




Figure S52. ¹³C NMR spectrum of (*R,S*)-G17 in CDCl₃ (100 MHz).




Figure S53. HSQC spectrum of (*R,S*)-G17 in CDCl₃.




Figure S54. HRMS spectrum of (*R,S*)-G17.




Figure S55. ¹H NMR spectrum of *(S,R)*-G18 in CDCl₃ (400 MHz).




Figure S56. ¹³C NMR spectrum of *(S,R)*-G18 in DMSO-*d*₆ (100 MHz).




Figure S57. HRMS spectrum of (S,R)-G18.




Figure S58. ¹H NMR spectrum of (R,S)-G18 in CDCl₃ (400 MHz).




Figure S59. ¹³C NMR spectrum of (R,S)-G18 in DMSO-*d*₆ (100 MHz).




Figure S60. ¹H-¹H COSY spectrum of (R,S)-G18 in CDCl₃ (400 MHz).




Figure S61. ^1H - ^1H COSY spectrum of (*R,S*)-G18 in $\text{DMSO-}d_6$ (400 MHz).




Figure S62. HSQC spectrum of (*R,S*)-G18 in $\text{DMSO-}d_6$.




Figure S63. HRMS spectrum of (R,S)-G18.




Figure S64. ¹H NMR spectrum of (S,R)-G19 in CDCl₃ (400 MHz).




Figure S65. ¹³C NMR spectrum of *(S,R)*-G19 in DMSO-*d*₆ (100 MHz).




Figure S66. HRMS spectrum of *(S,R)*-G19.




Figure S67. ¹H NMR spectrum of (R,S)-G19 in CDCl₃ (400 MHz).




Figure S68. ¹³C NMR spectrum of (R,S)-G19 in DMSO-*d*₆ (100 MHz).




Figure S69. ^1H - ^1H COSY spectrum of (*R,S*)-G19 in CDCl_3 (400 MHz).




Figure S70. HSQC spectrum of (*R,S*)-G19 in CDCl_3 containing 10% acetone- d_6 .




Figure S71. HRMS spectrum of (R,S)-G19.




Figure S72. ¹H NMR spectrum of (S,R)-G20 in CDCl₃ (400 MHz).




Figure S73. ¹³C NMR spectrum of *(S,R)*-G20 in DMSO-*d*₆ (100 MHz).




Figure S74. HRMS spectrum of *(S,R)*-G20.




Figure S75. ¹H NMR spectrum of (R,S)-G20 in CDCl₃ (400 MHz).




Figure S76. ¹³C NMR spectrum of (R,S)-G20 in DMSO-*d*₆.




Figure S77. ^1H - ^1H COSY spectrum of (*R,S*)-G20 in CDCl_3 containing 10% acetone- d_6 (400 MHz).




Figure S78. HSQC spectrum of (*R,S*)-G20 in CDCl_3 containing 10 % acetone- d_6 .




Figure S79. HRMS spectrum of (R,S)-G20.




Figure S80. ¹H NMR spectrum of (S,R)-G21 in CDCl₃ (400 MHz).




Figure S81. ^{13}C NMR spectrum of (*S,R*)-G21 in $\text{DMSO-}d_6$ (100 MHz).




Figure S82. HRMS spectrum of (*S,R*)-G21.




Figure S83. ¹H NMR spectrum of (R,S)-G21 in CDCl₃ (400 MHz).




Figure S84. ¹³C NMR spectrum of (R,S)-G21 in DMSO-*d*₆ (100 MHz).




Figure S85. ^1H - ^1H COSY spectrum of (*R,S*)-G21 in CDCl_3 (5% acetone- d_6), (400 MHz).




Figure S86. HSQC spectrum of (*R,S*)-G21 in CDCl_3 (5% acetone- d_6).




Figure S87. HRMS spectrum of (R,S)-G21.




Figure S88. ¹H NMR spectrum of (S,R)-G22 in CDCl₃ (400 MHz).




Figure S89. ¹³C NMR spectrum of (S,R)-G22 in CDCl₃ (100 MHz).




Figure S90. HRMS spectrum of (S,R)-G22.




Figure S91. ¹H NMR spectrum of (R,S)-G22 in CDCl₃ (400 MHz).




Figure S92. ¹³C NMR spectrum of (R,S)-G22 in CDCl₃ (100 MHz).




Figure S93. ^1H - ^1H COSY spectrum of (*R,S*)-G22 in CDCl_3 (400 MHz).




Figure S94. HSQC spectrum of (*R,S*)-G22 in CDCl_3 .




Figure S95. HRMS spectrum of (*R,S*)-G22.




Figure S96. ¹H NMR spectrum of (*S,R*)-G23 in CDCl₃ (400 MHz).




Figure S97. ¹³C NMR spectrum of (S,R)-G23 in DMSO-d₆ (100 MHz).




Figure S98. HRMS spectrum of (S,R)-G23.




Figure S99. ¹H NMR spectrum of (R,S)-G23 in CDCl₃ (400 MHz).




Figure S100. ¹³C NMR spectrum of (R,S)-G23 in DMSO-d₆ (100 MHz).




Figure S101. ^1H - ^1H COSY spectrum of (*R,S*)-G23 in CDCl_3 (400 MHz).




Figure S102. HSQC spectrum of (*R,S*)-G23 in CDCl_3 (5% acetone- d_6).




Figure S103. HRMS spectrum of (*R,S*)-G23.




Figure S104. ¹H NMR spectrum of (*S,R*)-G24 in CDCl₃ (400 MHz).




Figure S105. ¹³C NMR spectrum of (S,R)-G24 in DMSO-*d*₆ (100 MHz).




Figure S106. HRMS spectrum of (S,R)-G24.




Figure S107. ¹H NMR spectrum of (R,S)-G24 in CDCl₃ (400 MHz).




Figure S108. ¹³C NMR spectrum of (R,S)-G24 in CDCl₃ (5% acetone-*d*₆) (400 MHz).




Figure S109. ¹³C NMR spectrum of (R,S)-G24 in DMSO-*d*₆ (100 MHz).




Figure S110. ¹H-¹H COSY spectrum of (R,S)-G24 in CDCl₃ (400 MHz).




Figure S111. HSQC spectrum of (*R,S*)-G24 in CDCl₃ (5% acetone-*d*₆).




Figure S112. HRMS spectrum of (*R,S*)-G24.




Figure S113. ¹³C NMR spectrum of (S,R)-G25 in CDCl₃ (400 MHz).




Figure S114. ¹³C NMR spectrum of (S,R)-G25 in CDCl₃ (100 MHz).




Figure S115. HRMS spectrum of (*S,R*)-G25.




Figure S116. ¹H NMR spectrum of (*R,S*)-G25 in CDCl₃ (400 MHz).




Figure S117. ^{13}C NMR spectrum of (*R,S*)-G25 in CDCl_3 (100 MHz).




Figure S118. ^1H - ^1H COSY spectrum of (*R,S*)-G25 in CDCl_3 (400 MHz).




Figure S119. HSQC spectrum of (R,S)-G25 in CDCl₃.




Figure S120. HRMS spectrum of (R,S)-G25.




Figure S121. ¹H NMR spectrum of (S,R)-G26 in CDCl₃ (400 MHz).




Figure S122. ¹³C NMR spectrum of (S,R)-G26 in CDCl₃ (100 MHz).




Figure S123. HRMS spectrum of (*S,R*)-G26.




Figure S124. ¹H NMR spectrum of (*R,S*)-G26 in CDCl₃ (400 MHz).




Figure S125. ^{13}C NMR spectrum of (R,S)-G26 in CDCl_3 (100 MHz).




Figure S126. ^1H - ^1H COSY spectrum of (R,S)-G26 in CDCl_3 (400 MHz).




Figure S127. HSQC spectrum of (*R,S*)-G26 in CDCl₃.




Figure S128. HRMS spectrum of (*R,S*)-G26.




Figure S129. ^1H NMR spectrum of (*S,R*)-G27 in CDCl_3 (400 MHz).




Figure S130. ^{13}C NMR spectrum of (*S,R*)-G27 in CDCl_3 (100 MHz).




Figure S131. HRMS spectrum of (S,R)-G27.




Figure S132. ¹H NMR spectrum of (R,S)-G27 in CDCl₃ (400 MHz).




Figure S133. ¹³C NMR spectrum of (R,S)-G27 in CDCl₃ (100 MHz).




Figure S134. ¹H-¹H COSY spectrum of (R,S)-G27 in CDCl₃ (400 MHz).




Figure S135. HSQC spectrum of (*R,S*)-G27 in CDCl₃.




Figure S136. HRMS spectrum of (*R,S*)-G27.

¹H NMR spectra of enantiomeric discrimination of (±)-G16–27 in the presence of CSAs 1–9.




Figure S137. ¹H NMR spectrum of (±)-G16 in the presence of CSA 1 in CDCl₃ (400 MHz), [(±)-G16] = 5 mM.




Figure S138. ¹H NMR spectrum of (±)-G16 in the presence of CSA 2 in CDCl₃ (400 MHz), [(±)-G16] = 5 mM.




Figure S139. ^1H NMR spectrum of (\pm)-G16 in the presence of CSA 3 in CDCl_3 (400 MHz), [(\pm)-G16] = 5 mM.




Figure S140. ^1H NMR spectrum of (\pm)-G16 in the presence of CSA 4 in CDCl_3 (400 MHz), [(\pm)-G16] = 5 mM.




Figure S141. ^1H NMR spectrum of (\pm)-G16 in the presence of CSA 5 in CDCl_3 (400 MHz), [(\pm)-G16] = 5 mM.




Figure S142. ^1H NMR spectrum of (\pm)-G16 in the presence of CSA 6 in CDCl_3 (400 MHz), [(\pm)-G16] = 5 mM.




Figure S143. ^1H NMR spectrum of (\pm)-G16 in the presence of CSA 7 in CDCl_3 (400 MHz), [(\pm)-G16] = 5 mM.




Figure S144. ^1H NMR spectrum of (\pm)-G16 in the presence of CSA 8 in CDCl_3 (400 MHz), [(\pm)-G16] = 5 mM.




Figure S145. ^1H NMR spectrum of (\pm)-G16 in the presence of CSA **9** in CDCl_3 (400 MHz), [(\pm)-G16] = 5 mM.




Figure S146. ^1H NMR spectrum of (\pm)-G17 in the presence of CSA **1** in CDCl_3 (400 MHz), [(\pm)-G17] = 5 mM.




Figure S147. ^1H NMR spectrum of (±)-G17 in the presence of CSA 2 in CDCl_3 (400 MHz), [(±)-G17] = 5 mM.




Figure S148. ^1H NMR spectrum of (±)-G17 in the presence of CSA 3 in CDCl_3 (400 MHz), [(±)-G17] = 5 mM.




Figure S149. ^1H NMR spectrum of (\pm)-G17 in the presence of CSA 4 in CDCl_3 (400 MHz), [(\pm)-G17] = 5 mM.




Figure S150. ^1H NMR spectrum of (\pm)-G17 in the presence of CSA 5 in CDCl_3 (400 MHz), [(\pm)-G17] = 5 mM.




Figure S151. ^1H NMR spectrum of (\pm)-G17 in the presence of CSA 6 in CDCl_3 (400 MHz), [(\pm)-G17] = 5 mM.




Figure S152. ^1H NMR spectrum of (\pm)-G17 in the presence of CSA 7 in CDCl_3 (400 MHz), [(\pm)-G17] = 5 mM.




Figure S153. ¹H NMR spectrum of (±)-G17 in the presence of CSA 8 in CDCl₃ (400 MHz), [(±)-G17] = 5 mM.




Figure S154. ¹H NMR spectrum of (±)-G17 in the presence of CSA 9 in CDCl₃ (400 MHz), [(±)-G17] = 5 mM.




Figure S155. ^1H NMR spectrum of (±)-G18 in the presence of CSA 3 in CDCl_3 (400 MHz), [(±)-G18] = 5 mM.




Figure S156. ^1H NMR spectrum of (±)-G18 in the presence of CSA 4 in CDCl_3 (400 MHz), [(±)-G18] = 5 mM.




Figure S157. ¹H NMR spectrum of (±)-G18 in the presence of CSA 5 in CDCl₃ (400 MHz), [(±)-G18] = 5 mM.




Figure S158. ¹H NMR spectrum of (±)-G18 in the presence of CSA 7 in CDCl₃ (400 MHz), [(±)-G18] = 5 mM.




Figure S159. ^1H NMR spectrum of (\pm)-G18 in the presence of CSA 8 in CDCl_3 (400 MHz), [(\pm)-G18] = 5 mM.




Figure S160. ^1H NMR spectrum of (\pm)-G18 in the presence of CSA 9 in CDCl_3 (400 MHz), [(\pm)-G18] = 5 mM.




Figure S161. ^1H NMR spectrum of (\pm)-G19 in the presence of CSA 1 in CDCl_3 (400 MHz), [(\pm)-G19] = 5 mM.




Figure S162. ^1H NMR spectrum of (\pm)-G19 in the presence of CSA 2 in CDCl_3 (400 MHz), [(\pm)-G19] = 5 mM.




Figure S163. ^1H NMR spectrum of (\pm)-**G19** in the presence of CSA **3** in CDCl_3 (400 MHz), [(\pm)-**G19**] = 5 mM.






Figure S164. ^1H NMR spectrum of (\pm)-**G19** in the presence of CSA **4** in CDCl_3 (400 MHz), [(\pm)-**G19**] = 5 mM.






Figure S167. ^1H NMR spectrum of (\pm)-**G19** in the presence of CSA **7** in CDCl_3 (400 MHz), [(\pm)-**G19**] = 5 mM.




Figure S168. ^1H NMR spectrum of (\pm)-**G19** in the presence of CSA **8** in CDCl_3 (400 MHz), [(\pm)-**G19**] = 5 mM.




Figure S169. ^1H NMR spectrum of (±)-G19 in the presence of CSA 9 in CDCl_3 (400 MHz), [(±)-G19] = 5 mM.




Figure S170. ^1H NMR spectrum of (±)-G20 in the presence of CSA 1 in CDCl_3 (400 MHz), [(±)-G20] = 5 mM.




Figure S171. ¹H NMR spectrum of (±)-G20 in the presence of CSA 2 in CDCl₃ (400 MHz), [(±)-G20] = 5 mM.




Figure S172. ¹H NMR spectrum of (±)-G20 in the presence of CSA 3 in CDCl₃ (400 MHz), [(±)-G20] = 5 mM.




Figure S173. ^1H NMR spectrum of (\pm)-G20 in the presence of CSA 4 in CDCl_3 (400 MHz), [(\pm)-G20] = 5 mM.




Figure S174. ^1H NMR spectrum of (\pm)-G20 in the presence of CSA 5 in CDCl_3 (400 MHz), [(\pm)-G20] = 5 mM.




Figure S175. ^1H NMR spectrum of (\pm)-G20 in the presence of CSA **7** in CDCl_3 (400 MHz), [\pm]-G20 = 5 mM.




Figure S176. ^1H NMR spectrum of (\pm)-G20 in the presence of CSA **8** in CDCl_3 (400 MHz), [\pm]-G20 = 5 mM.




Figure S177. ^1H NMR spectrum of (\pm)-G20 in the presence of CSA **9** in CDCl_3 (400 MHz), [(\pm)-G20] = 5 mM.




Figure S178. ^1H NMR spectrum of (\pm)-G21 in the presence of CSA **1** in CDCl_3 (400 MHz), [(\pm)-G21] = 5 mM.




Figure S179. ^1H NMR spectrum of (\pm)-G21 in the presence of CSA 2 in CDCl_3 (400 MHz), [(\pm)-G21] = 5 mM.




Figure S180. ^1H NMR spectrum of (\pm)-G21 in the presence of CSA 3 in CDCl_3 (400 MHz), [(\pm)-G21] = 5 mM.




Figure S181. ^1H NMR spectrum of (\pm)-G21 in the presence of CSA 4 in CDCl_3 (400 MHz), [(\pm)-G21] = 5 mM.




Figure S182. ^1H NMR spectrum of (\pm)-G21 in the presence of CSA 5 in CDCl_3 (400 MHz), [(\pm)-G21] = 5 mM.




Figure S183. ^1H NMR spectrum of (±)-G21 in the presence of CSA 6 in CDCl_3 (400 MHz), [(±)-G21] = 5 mM.




Figure S184. ^1H NMR spectrum of (±)-G21 in the presence of CSA 7 in CDCl_3 (400 MHz), [(±)-G21] = 5 mM.




Figure S187. ^1H NMR spectrum of (±)-G22 in the presence of CSA 1 in CDCl_3 (400 MHz), [(±)-G22] = 5 mM.




Figure S188. ^1H NMR spectrum of (±)-G22 in the presence of CSA 2 in CDCl_3 (400 MHz), [(±)-G22] = 5 mM.




Figure S189. ^1H NMR spectrum of (\pm)-G22 in the presence of CSA 3 in CDCl_3 (400 MHz), [(\pm)-G22] = 5 mM.




Figure S190. ^1H NMR spectrum of (\pm)-G22 in the presence of CSA 4 in CDCl_3 (400 MHz), [(\pm)-G22] = 5 mM.




Figure S191. ^1H NMR spectrum of (\pm)-G22 in the presence of CSA 5 in CDCl_3 (400 MHz), [\pm]-G22 = 5 mM.




Figure S192. ^1H NMR spectrum of (\pm)-G22 in the presence of CSA 6 in CDCl_3 (400 MHz), [\pm]-G22 = 5 mM.




Figure S193. ¹H NMR spectrum of (±)-G22 in the presence of CSA 7 in CDCl₃ (400 MHz), [(±)-G22] = 5 mM.




Figure S194. ¹H NMR spectrum of (±)-G22 in the presence of CSA 8 in CDCl₃ (400 MHz), [(±)-G22] = 5 mM.




Figure S195. ^1H NMR spectrum of (\pm)-G22 in the presence of CSA **9** in CDCl_3 (400 MHz), [(\pm)-G22] = 5 mM.




Figure S196. ^1H NMR spectrum of (\pm)-G23 in the presence of CSA **1** in CDCl_3 (400 MHz), [(\pm)-G23] = 4 mM.




Figure S197. ^1H NMR spectrum of (\pm)-G23 in the presence of CSA 2 in CDCl_3 (400 MHz), [(\pm)-G23] = 4 mM.




Figure S198. ^1H NMR spectrum of (\pm)-G23 in the presence of CSA 3 in CDCl_3 (400 MHz), [(\pm)-G23] = 4 mM.




Figure S199. ^1H NMR spectrum of (\pm)-G23 in the presence of CSA 4 in CDCl_3 (400 MHz), [(\pm)-G23] = 4 mM.




Figure S200. ^1H NMR spectrum of (\pm)-G23 in the presence of CSA 5 in CDCl_3 (400 MHz), [(\pm)-G23] = 4 mM.




Figure S201. ^1H NMR spectrum of (\pm)-G23 in the presence of CSA 7 in CDCl_3 (400 MHz), [\pm]-G23 = 4 mM.




Figure S202. ^1H NMR spectrum of (\pm)-G23 in the presence of CSA 8 in CDCl_3 (400 MHz), [\pm]-G23 = 4 mM.




Figure S203. ^1H NMR spectrum of (\pm)-G23 in the presence of CSA 9 in CDCl_3 (400 MHz), [(\pm)-G23] = 4 mM.




Figure S204. ^1H NMR spectrum of (\pm)-G24 in the presence of CSA 1 in CDCl_3 (400 MHz), [(\pm)-G24] = 2.5 mM.




Figure S205. ^1H NMR spectrum of (\pm)-G24 in the presence of CSA 4 in CDCl_3 (400 MHz), [(\pm)-G24] = 2.5 mM.




Figure S206. ^1H NMR spectrum of (\pm)-G24 in the presence of CSA 5 in CDCl_3 (400 MHz), [(\pm)-G24] = 2.5 mM.




Figure S207. ^1H NMR spectrum of (\pm)-G24 in the presence of CSA 7 in CDCl_3 (400 MHz), [\pm]-G24 = 2.5 mM.




Figure S208. ^1H NMR spectrum of (\pm)-G24 in the presence of CSA 8 in CDCl_3 (400 MHz), [\pm]-G24 = 2.5 mM.




Figure S209. ^1H NMR spectrum of (\pm)-G24 in the presence of CSA **9** in CDCl_3 (400 MHz), [(\pm)-G24] = 2.5 mM.




Figure S210. ^1H NMR spectrum of (\pm)-G25 in the presence of CSA **1** in CDCl_3 (400 MHz), [(\pm)-G25] = 5 mM.




Figure S211. ^1H NMR spectrum of (\pm)-G25 in the presence of CSA 3 in CDCl_3 (400 MHz), [(\pm)-G25] = 5 mM.






Figure S212. ^1H NMR spectrum of (\pm)-G25 in the presence of CSA 4 in CDCl_3 (400 MHz), [(\pm)-G25] = 5 mM.






Figure S215. ^1H NMR spectrum of (±)-G25 in the presence of CSA 7 in CDCl_3 (400 MHz), [(±)-G25] = 5 mM.




Figure S216. ^1H NMR spectrum of (±)-G25 in the presence of CSA 8 in CDCl_3 (400 MHz), [(±)-G25] = 5 mM.




Figure S217. ^1H NMR spectrum of (±)-G25 in the presence of CSA 9 in CDCl_3 (400 MHz), [(±)-G25] = 5 mM.




Figure S218. ^1H NMR spectrum of (±)-G26 in the presence of CSA 3 in CDCl_3 (400 MHz), [(±)-G26] = 5 mM.




Figure S219. ^1H NMR spectrum of (\pm)-G26 in the presence of CSA 6 in CDCl_3 (400 MHz), [\pm]-G26 = 5 mM.




Figure S220. ^1H NMR spectrum of (\pm)-G26 in the presence of CSA 7 in CDCl_3 (400 MHz), [\pm]-G26 = 5 mM.




Figure S221. ^1H NMR spectrum of (\pm)-G26 in the presence of CSA 8 in CDCl_3 (400 MHz), [(\pm)-G26] = 5 mM.




Figure S222. ^1H NMR spectrum of (\pm)-G26 in the presence of CSA 9 in CDCl_3 (400 MHz), [(\pm)-G26] = 5 mM.




Figure S223. ^1H NMR spectrum of (±)-G27 in the presence of CSA 1 in CDCl_3 (400 MHz), [(±)-G27] = 5 mM.




Figure S224. ^1H NMR spectrum of (±)-G27 in the presence of CSA 2 in CDCl_3 (400 MHz), [(±)-G27] = 5 mM.




Figure S225. ^1H NMR spectrum of (±)-G27 in the presence of CSA 3 in CDCl_3 (400 MHz), [(±)-G27] = 5 mM.




Figure S226. ^1H NMR spectrum of (±)-G27 in the presence of CSA 4 in CDCl_3 (400 MHz), [(±)-G27] = 5 mM.




Figure S227. ^1H NMR spectrum of (±)-G27 in the presence of CSA 5 in CDCl_3 (400 MHz), [(±)-G27] = 5 mM.




Figure S228. ^1H NMR spectrum of (±)-G27 in the presence of CSA 6 in CDCl_3 (400 MHz), [(±)-G27] = 5 mM.




Figure S229. ^1H NMR spectrum of (\pm)-G27 in the presence of CSA 7 in CDCl_3 (400 MHz), [(\pm)-G27] = 5 mM.




Figure S230. ^1H NMR spectrum of (\pm)-G27 in the presence of CSA 8 in CDCl_3 (400 MHz), [(\pm)-G27] = 5 mM.




Figure S231. ^1H NMR spectrum of (±)-G27 in the presence of CSA 9 in CDCl_3 (400 MHz), [(±)-G27] = 5 mM.